Natural Health Products and Diabetes: A Practical Review

Canadian Journal of Diabetes

Volumn 41, Issue 6, 2017, Pages 642-647

  Necyk, Candace ^a   Zubach Cassano, Leyanna ^b  

^a UNIVERSITY OF ALBERTA   (Canada)

^b Redefined Health   (Canada)

Author keywords

Complementary and alternative medicine; diabetes management; efficacy; Herbs; natural health products; Nutrients; safety

Indexed keywords

ANTIBIOTIC AGENT; BISPHOSPHONIC ACID DERIVATIVE; CHROMIUM; CHROMIUM DERIVATIVE; CHROMIUM GLUCOSE TOLERANCE FACTOR; CHROMIUM PICOLINATE; MAGNESIUM; MAGNESIUM BISGLYCINATE; MAGNESIUM DERIVATIVE; NATURAL HEALTH PRODUCT; NATURAL PRODUCT; PLACEBO; POTASSIUM SPARING DIURETIC AGENT; SILYMARIN; THIOCTIC ACID; UNCLASSIFIED DRUG; BIOLOGICAL PRODUCT;

ANTIDIABETIC ACTIVITY; CANADA; CINNAMON; DIABETES MELLITUS; DRUG EFFICACY; DRUG SAFETY; FENUGREEK; GANODERMA LUCIDUM; GYMNEMA; HEALTH CARE PERSONNEL; HUMAN; MINERAL DEFICIENCY; MOMORDICA CHARANTIA; MORUS ALBA; NAUSEA; NONHUMAN; PATIENT CARE; PATIENT EDUCATION; PERIPHERAL NEUROPATHY; REVIEW; SILYBUM MARIANUM; VERTIGO; VOMITING; BLOOD; CHEMICALLY INDUCED; HYPOGLYCEMIA;

BIOLOGICAL PRODUCTS; CANADA; DIABETES MELLITUS; HUMANS; HYPOGLYCEMIA;

EID: 85027582672     PISSN: 14992671     EISSN: 23523840     Source Type: Journal    
DOI: 10.1016/j.jcjd.2017.06.014     Document Type: Review

References (77)

1. Health Canada, Natural and non-prescription health products. Updated December 8 https://www.canada.ca/en/health-canada/services/drugs-health-products/natural-non-prescription.html, 2016 Accessed May 20, 2017.
2. Natural Health Products Directorate—Health Canada, Natural Health Product Tracking Survey-2010 Final Report. Ipsos-Reid. March 13 http://epe.lac-bac.gc.ca/100/200/301/pwgsc-tpsgc/por-ef/health/2011/135-09/report.pdf, 2011. (Accessed 21 May 2017)
3. Geil, P., Shane-McWhorter, L., Dietary supplements in the management of diabetes: Potential risks and benefits. J Am Diet Assoc 108:4 Suppl. 1 (2008), S59–65.
4. Alherbish, A., Charrois, T.L., Ackman, M.L., et al. The prevalence of natural health product use in patients with acute cardiovascular disease. PLoS ONE, 6, 2011 e19623.
5. Felix, S., 2015 OTC Market Report: Vitamins, minerals and supplements. Pharmacy Practice Plus. April http://www.canadianhealthcarenetwork.ca/pharmacists/magazines/pharmacy-practice-plus/april-2015/2015-otc-market-report-vitamins-minerals-and-supplements-31185, 2015. (Accessed 20 May 2017)
6. Nahas, R., Goguen, J., Natural Health Products. Canadian Diabetes Association Clinical Practice Guidelines. Can J Diabetes 37:Suppl. 1 (2013), S97–99 http://guidelines.diabetes.ca/app_themes/cdacpg/resources/cpg_2013_full_en.pdf/ Accessed on April 25, 2017.
7. Yilmaz, Z., Piracha, F., Anderson, L., Mazzola, N., Supplements for diabetes mellitus: A review of the literature. J Pharm Pract, 2016 in press.
8. Bi, X., Lim, J., Henry, C.J., Spices in the management of diabetes mellitus. Food Chem 217 (2017), 281–293.
9. Deng, R., A review of the hypoglycemic effects of five commonly used herbal food supplements. Recent Pat Food Nutr Agric 4 (2012), 50–60.
10. Packer, L., Witt, E.H., Tritschler, H.J., Alpha-lipoic acid as a biological antioxidant. Free Radic Biol Med 19 (1995), 227–250.
11. Vincent, H.K., Bourguignon, C.M., Vincent, K.R., Taylor, A.G., Effects of alpha-lipoic acid supplementation in peripheral arterial disease: A pilot study. J Alt Complement Med 13 (2007), 577–584.
12. Golbidi, S., Badran, M., Laher, I., Diabetes and alpha lipoic acid. Front Pharmacol, 2, 2011, 69.
13. Han, T., Bai, J., Liu, W., Hu, Y., A systematic review and meta-analysis of α-lipoic acid in the treatment of diabetic peripheral neuropathy. Eur J Endocrinol 167 (2012), 465–471.
14. Ziegler, D., Ametov, A., Barinov, A., et al. Oral treatment with alpha-lipoic acid improves symptomatic diabetic polyneuropathy: The SYDNEY 2 trial. Diabetes Care 29 (2006), 2365–2370.
15. Tang, J., Wingerchuk, D.M., Crum, B.A., et al. Alpha-lipoic acid may improve symptomatic diabetic polyneuropathy. Neurologist 13 (2007), 164–167.
16. Labriola, D., Livingston, R., Possible interactions between dietary antioxidants and chemotherapy. Oncology 13 (1999), 1003–1008.
17. Segermann, J., Hotze, A., Ulrich, H., Rao, G.S., Effect of alpha-lipoic acid on the peripheral conversion of thyroxine to triiodothyronine and on serum lipid-, protein- and glucose levels. Arzneimittelforschung 41 (1991), 1294–1298.
18. Konrad, T., Vicini, P., Kusterer, K., et al. Alpha-lipoic acid treatment decreases serum lactate and pyruvate concentrations and improves glucose effectiveness in lean and obese patients with type 2 diabetes. Diabetes Care 22 (1999), 280–287.
19. Yin, R.V., Phung, O.J., Effect of chromium supplementation on glycated hemoglobin and fasting plasma glucose in patients with diabetes mellitus. Nutr J, 14, 2015, 14.
20. Rafiei, R., Habyby, Z., Fouladi, L., et al. Chromium level in prediction of diabetes in pre-diabetic patients. Adv Biomed Res, 3, 2014, 235.
21. Paiva, A.N., Lima, J.G., Medeiros, A.C., et al. Beneficial effects of oral chromium picolinate supplementation on glycemic control in patients with type 2 diabetes: A randomized clinical study. J Trace Elem Med Biol 32 (2015), 66–72.
22. Suksomboon, N., Poolsup, N., Yuwanakorn, A., Systematic review and meta-analysis of the efficacy and safety of chromium supplementation in diabetes. J Clin Pharm Ther 39 (2014), 292–306.
23. Amato, P., Morales, A., Yen, S.S., Effects of chromium picolinate supplementation on insulin sensitivity, serum lipids, and body composition in healthy, nonobese, older men and women. J Gerontol A Biol Sci Med Sci 55 (2000), M260–3.
24. Cerulli, J., Grabe, D.W., Gauthier, I., et al. Chromium picolinate toxicity. Ann Pharmacother 32 (1998), 428–431.
25. Cefalu, W.T., Hu, F.B., Role of chromium in human health and in diabetes. Diabetes Care 27 (2004), 2741–2751.
26. John-Kalarickal, J., Pearlman, G., Carlson, H.E., New medications which decrease levothyroxine absorption. Thyroid 17 (2007), 763–765.
27. Volpe, S.L., Magnesium in disease prevention and overall health. Adv Nutr 4 (2013), 378S–383S.
28. Barbagallo, M., Dominguez, L.J., Magnesium and type 2 diabetes. World J Diabetes 6 (2015), 1152–1157.
29. Seibrecht, S., Magnesium bisglycinate as safe form for mineral supplementation in human nutrition. Int J Orthomol Relat Med, 144, 2013, 16.
30. Firoz, M., Graber, M., Bioavailability of US commercial magnesium preparations. Magnes Res 14 (2001), 257–262.
31. Heidenreich, O., Mode of action of conventional and potassium-sparing diuretics–aspects with relevance to Mg-sparing effects. Magnesium 3 (1984), 248–256.
32. Hansten, P.D., Horn, J.R., Drug interactions analysis and management. 1997, Applied Therapeutics Inc., Vancouver, WA and updates.
33. Sompolinsky, D., Samra, Z., Influence of magnesium and manganese on some biological and physical properties of tetracycline. J Bacteriol 110 (1972), 468–476.
34. Dunn, C.J., Goa, K.L., Risedronate: A review of its pharmacological properties and clinical use in resorptive bone disease. Drugs 61 (2001), 685–712.
35. Joseph, B., Jini, D., Antidiabetic effects of Momordica charantia (bitter melon) and its medicinal potency. Asian Pac J Trop Dis 3 (2013), 93–102.
36. Dans, A.M., Villarruz, M.V., Jimeno, C.A., et al. The effect of Momordica charantia capsule preparation on glycemic control in type 2 diabetes mellitus needs further studies. J Clin Epidemiol 60 (2007), 554–559.
37. Ahmad, N., Hassan, M.R., Halder, H., Bennoor, K.S., Effect of Momordica charantia (Karolla) extracts on fasting and postprandial serum glucose levels in NIDDM patients [abstract]. Bangladesh Med Res Counc Bull 25 (1999), 11–13.
38. Medagama, A.B., Bandara, R., The use of complementary and alternative medicines (CAMs) in the treatment of diabetes mellitus: Is continued use safe and effective?. Nutr J, 13, 2014, 102.
39. Mang, B.1., Wolters, M., Schmitt, B., et al. Effects of a cinnamon extract on plasma glucose, HbA, and serum lipids in diabetes mellitus type 2. Eur J Clin Invest 36 (2006), 340–344.
40. Allen, R.W., Schwartzman, E., Baker, W.L., et al. Cinnamon use in type 2 diabetes: An updated systematic review and meta-analysis. Ann Fam Med 11 (2013), 452–459.
41. Felter, S.P., Vassallo, J.D., Carlton, B.D., et al. A safety assessment of coumarin taking into account species-specificity of toxicokinetics. Food Chem Toxicol 44 (2006), 462–475.
42. Marles, R.J., Farnsworth, N.R., Antidiabetic plants and their active constituents. Phytomedicine 2 (1995), 137–189.
43. Neelakantan, N., Narayanan, M., de Souza, R.J., et al. Effect of fenugreek (Trigonella foenum-graecum L.) intake on glycemia: A meta-analysis of clinical trials. Nutr J, 13, 2014, 7.
44. Gupta, A., Gupta, R., Lal, B., Effect of Trigonella foenum-graecum (fenugreek) seeds on glycaemic control and insulin resistance in type 2 diabetes mellitus: A double blind placebo controlled study. J Assoc Physicians India 49 (2001), 1057–1061.
45. Gaddam, A., Galla, C., Thummisetti, S., et al. Role of fenugreek in the prevention of type 2 diabetes mellitus in prediabetes. J Diabetes Metab Disord, 14, 2015, 74.
46. Lambert, J., Cormier, J., Potential interaction between warfarin and boldo-fenugreek. Pharmacotherapy 21 (2001), 509–512.
47. Al-Jenoobi, F.I., Ahad, A., Mahrous, G.M., et al. Effects of fenugreek, garden cress, and black seed on theophylline pharmacokinetics in beagle dogs. Pharm Biol 53 (2015), 296–300.
48. Kanetkar, P., Singhal, R., Kamat, M., Gymnema sylvestre: A memoir. J Clin Biochem Nutr 41 (2007), 77–81.
49. Tiwari, P., Mishra, B.N., Sangwan, N.S., Phytochemical and pharmacological properties of Gymnema sylvestre: An important medicinal plant. Biomed Res Int, 2014, 2014, 830285.
50. Shanmugasundaram, E.R., Rajeswari, G., Baskaran, K., et al. Use of Gymnema sylvestre leaf extract in the control of blood glucose in insulin-dependent diabetes mellitus. J Ethnopharmacol 30 (1990), 281–294.
51. Baskaran, K., Kizar Ahamath, B., Radha Shanmugasundaram, K., Shanmugasundaram, E.R., Antidiabetic effect of leaf extract from Gymnema sylvestre in non-insulin-dependent diabetes mellitus patients. J Ethnopharmacol 30 (1990), 295–300.
52. Giese, L., Complementary healthcare practices: Milk thistle and the treatment of hepatitis. Gastroenterol Nurs 24 (2001), 95–97.
53. Kazazis, C.E., Evangelopoulos, A.A., Kollas, A., et al. The therapeutic potential of milk thistle in diabetes. Rev Diabet Stud 11 (2014), 167–174.
54. Huseini, H.F., Larijani, B., Heshmat, R., et al. The efficacy of Silybum marianum (L.) Gaertn. (silymarin) in the treatment of type II diabetes: A randomized, double-blind, placebo-controlled, clinical trial. Phytother Res 20 (2006), 1036–1039.
55. Fallahzadeh, M.K., Dormanesh, B., Sagheb, M.M., et al. Effect of addition of silymarin to renin-angiotensin system inhibitors on proteinuria in type 2 diabetic patients with overt nephropathy: A randomized, double-blind, placebo-controlled trial. Am J Kidney Dis 60 (2012), 896–903.
56. Sonnenbichler, J., Scalera, F., Sonnenbichler, I., et al. Stimulatory effects of silibinin and silicristin from the milk thistle Silybum marianum on kidney cells. J Pharmacol Exp Ther 290 (1999), 1375–1383.
57. Fried, M.W., Navarro, V.J., Afdhal, N., et al. Effect of silymarin (milk thistle) on liver disease in patients with chronic hepatitis C unsuccessfully treated with interferon therapy: A randomized controlled trial. JAMA 308 (2012), 274–282.
58. Venkataramanan, R., Ramachandran, V., Komoroski, B.J., et al. Milk thistle, a herbal supplement, decreases the activity of CYP3A4 and uridine diphosphoglucuronosyl transferase in human hepatocyte cultures. Drug Metab Dispos 28 (2000), 1270–1273.
59. Kim, C.S., Choi, S.J., Park, C.Y., et al. Effects of silybinin on the pharmacokinetics of tamoxifen and its active metabolite, 4-hydroxytamoxifen in rats. Anticancer Res 30 (2010), 79–85.
60. Gufford, B.T., Chen, G., Vergara, A.G., et al. Milk thistle constituents inhibit raloxifene intestinal glucuronidation: A potential clinically relevant natural product-drug interaction. Drug Metab Dispos 43 (2015), 1353–1359.
61. Jiao, Z., Shi, X.J., Li, Z.D., et al. Population pharmacokinetics of sirolimus in de novo Chinese adult renal transplant patients. Br J Clin Pharmacol 68 (2009), 47–60.
62. Seidlová-Wuttke, D., Becker, T., Christoffel, V., et al. Silymarin is a selective estrogen receptor beta (ERbeta) agonist and has estrogenic effects in the metaphysis of the femur but no or antiestrogenic effects in the uterus of ovariectomized (ovx) rats. J Steroid Biochem Mol Biol 86 (2003), 179–188.
63. Deng, J.W., Shon, J.H., Shin, H.J., et al. Effect of silymarin supplement on the pharmacokinetics of rosuvastatin. Pharm Res 25 (2008), 1807–1814.
64. Benzie, I.F.F., Wachtel-Galor, S., (eds.) Herbal medicine: biomolecular and clinical aspects, 2nd edn, 2011, CRC Press/Taylor & Francis, Boca Raton.
65. Gao, Y., Lan, J., Dai, X., et al. A phase I/II study of Ling Zhi mushroom Ganoderma lucidum (W.Curt.:Fr.)Lloyd (Aphyllophoromycetideae) extract in patients with type II diabetes mellitus. Int J Med Mushrooms 6 (2004), 33–39.
66. Tao, J., Feng, K.Y., Experimental and clinical studies on inhibitory effect of ganoderma lucidum on platelet aggregation. J Tongji Med Univ 10:4 (1990), 240–243.
67. Jin, H., Zhang, G., Cao, X., et al. Treatment of hypertension by linzhi combined with hypotensor and its effects on arterial, arteriolar and capillary pressure and microcirculation. Niimi, H., Xiu, R.J., Sawada, T., et al. (eds.) Microcirculatory approach to asian traditional medicine, 1996, Elsevier Science, New York.
68. Kojima, Y., Kimura, T., Nakagawa, K., et al. Effects of mulberry leaf extract rich in 1-deoxynojirimycin on blood lipid profiles in humans. J Clin Biochem Nutr 47 (2010), 155–161.
69. Asai, A., Nakagawa, K., Higuchi, O., et al. Effect of mulberry leaf extract with enriched 1-deoxynojirimycin content on postprandial glycemic control in subjects with impaired glucose metabolism. J Diabetes Investig 2 (2011), 318–323.
70. Mudra, M., Ercan-Fang, N., Zhong, L., et al. Influence of mulberry leaf extract on the blood glucose and breath hydrogen response to ingestion of 75 g sucrose by type 2 diabetic and control subjects. Diabetes Care 30 (2007), 1272–1274.
71. Kimura, T., Nakagawa, K., Kubota, H., et al. Food-grade mulberry powder enriched with 1-deoxynojirimycin suppresses the elevation of postprandial blood glucose in humans. J Agric Food Chem 55 (2007), 5869–5874.
72. Canadian Diabetes Association Clinical Practice Guidelines Expert Committee, Stone, J.A., Fitchett, D., et al. Vascular protection in people with diabetes. Can J Diabetes 37 (2013), S100–4.
73. Canadian Diabetes Association Clinical Practice Guidelines Expert Committee, McFarlane, P., Gilbert, R.E., et al. Chronic kidney disease in diabetes. Can J Diabetes 37 (2013), S129–36.
74. Canadian Association of Naturopathic Doctors. http://www.cand.ca/ Accessed May 31, 2017.
75. Natural Medicines Comprehensive Database. Updated June 26 http://naturaldatabase.therapeuticresearch.com/home.aspx?cs=cepda&s=ND, 2017. (Accessed 27 June 2017)
76. National Center for Complementary and Integrative Health. Updated Feb 22 https://nccih.nih.gov/, 2016. (Accessed 31 May 2017)
77. Health Canada, Natural Health Products Ingredients Database. http://webprod.hc-sc.gc.ca/nhpid-bdipsn/search-rechercheReq.do. (Accessed 31 May 2017)